Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer

Area of Science:

• Oncology
• Immunology
• Therapeutic Antibody Development

Background:

• Ovarian cancer presents limited effective treatment options, with immunotherapies showing suboptimal response rates.
• LY6/PLAUR domain containing 1 (LYPD1) is identified as a promising therapeutic target, broadly expressed in ovarian cancers, particularly serous subtypes.
• Bispecific antibodies targeting CD3 on T cells have shown efficacy in hematologic malignancies, suggesting potential for solid tumors.

Purpose of the Study:

• To investigate LYPD1 as a novel therapeutic target for ovarian cancer.
• To develop and characterize an anti-LYPD1/CD3 T-cell-dependent bispecific antibody (TDB) for ovarian cancer treatment.
• To evaluate the nonclinical pharmacology, efficacy, and safety of the anti-LYPD1/CD3 TDB.

Main Methods:

• Development of a bispecific antibody targeting LYPD1 on ovarian cancer cells and CD3 on T cells.
• Assessment of T-cell activation and killing of LYPD1-expressing ovarian cancer cells in vitro.
• Evaluation of in vivo antitumor efficacy in PBMC-reconstituted immune-deficient mice and human CD3 transgenic mouse models.
• Toxicology studies in mice to assess tolerability and identify potential off-target effects.

Main Results:

• The anti-LYPD1/CD3 TDB induced robust polyclonal T-cell activation.
• Target-dependent killing of LYPD1-expressing ovarian cancer cells was observed in vitro.
• Significant in vivo antitumor responses were achieved in preclinical models.
• The anti-LYPD1/CD3 TDB was well-tolerated at high doses in mice, with no observed toxicity in LYPD1-expressing tissues.

Conclusions:

• LYPD1 is a viable and broadly expressed target for ovarian cancer therapy.
• The anti-LYPD1/CD3 TDB demonstrates potent preclinical efficacy and a favorable safety profile.
• This TDB represents a promising novel therapeutic strategy for ovarian cancer treatment.